Form 13-F position report

KIORA PHARMACEUTICALS INC COM

Reported by MORGAN STANLEY

KPRX CUSIP 49721T309 Manager CIK 0000895421

Reported 0 shares, down 8 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 11 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 0
2022-03-31 0
2022-06-30 0
2022-09-30 0
2022-09-30 15000
2022-12-31 397
2023-03-31 27
2023-06-30 5
2023-09-30 5
2023-12-31 4
2024-03-31 6
2024-06-30 0
2024-06-30 4
2024-09-30 0
2025-03-31 2107
2025-06-30 0
2026-03-31 2717
2026-06-30 3703
2026-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for KIORA PHARMACEUTICALS INC COM held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 0 -1,408 (-100.0%) 0 $0 2026-11-13
Q2 2026 Unchanged 1,408 0 (0.0%) < 0.01% $3,703 2026-08-13
Q1 2026 New 1,408 +1,408 (0.0%) < 0.01% $2,717 2026-05-15
Q2 2025 Reduced 0 -700 (-100.0%) 0 $0 2025-08-15
Q1 2025 New 700 +700 (0.0%) < 0.01% $2,107 2025-05-15
Q3 2024 Reduced 0 -1 (-100.0%) 0 $0 2024-11-14
Q2 2024 New 1 +1 (0.0%) < 0.01% $4 2024-08-14
Q2 2024 Reduced 0 -8 (-100.0%) 0 $0 2024-08-14
Q1 2024 Unchanged 8 0 (0.0%) < 0.01% $6 2024-05-15
Q4 2023 Unchanged 8 0 (0.0%) < 0.01% $4 2024-02-13
Q3 2023 Unchanged 8 0 (0.0%) < 0.01% $5 2023-11-15
Q2 2023 Unchanged 8 0 (0.0%) < 0.01% $5 2023-08-14
Q1 2023 Reduced 8 -108 (-93.1%) < 0.01% $27 2023-05-15
Q4 2022 Reduced 116 -2,258 (-95.1%) < 0.01% $397 2023-02-14
Q3 2022 New 2,374 +2,374 (0.0%) < 0.01% $15,000 2022-11-14
Q3 2022 Reduced 0 -333 (-100.0%) 0 $0 2022-11-14
Q2 2022 Reduced 333 -16 (-4.6%) 0 $0 2022-08-15
Q1 2022 Added 349 +348 (34800.0%) 0 $0 2022-05-13
Q4 2021 New 1 +1 (0.0%) 0 $0 2022-02-14

Who else reported the position

26 managers reported KIORA PHARMACEUTICALS INC COM for Q2 2024.

Managers reporting KIORA PHARMACEUTICALS INC COM in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Rosalind Advisors Inc Unchanged 255,555 0 0.83% $1,073,331 2 qtrs
Stonepine Capital Management LLC New 200,000 +200,000 0.77% $840,000 1 qtr
Nantahala Capital Management LLC Reduced 0 -1,900,000 0 $0 2 qtrs
TWO SIGMA INVESTMENTS LP Reduced 0 -10,351 0 $0 2 qtrs
ADAR1 Capital Management LLC Reduced 0 -1,100,000 0 $0 2 qtrs
BlackRock Inc Reduced 0 -14,461 0 $0 8 qtrs
Velan Capital Investment Management LP Reduced 0 -1,100,000 0 $0 2 qtrs
CONCOURSE FINANCIAL GROUP SECURITIES INC Unchanged 0 0 0 $0 8 qtrs
ALBION FINANCIAL GROUP UT Reduced 0 -6 0 $0 8 qtrs
XTX Topco Ltd Reduced 0 -24,909 0 $0 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.